With its eyes set on an IPO raise, InCarda unrolls mid-stage data backing inhaled arrhythmia drug
Working to craft an old arrythmia drug into a more user-friendly inhaled formulation, InCarda is expecting to use new Phase II data revealed Wednesday as the foundation of a potential IPO raise.
The program, repurposing the oral and IV drug flecainide into an inhalant, completed the latest cohort of its Phase II study with 50% of patients successfully converting their irregular heartbeat episodes back to normal rhythm within 90 minutes, the San Francisco biotech said. That endpoint will be the primary goal in a pivotal Phase III study, expected to begin by the end of September.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.